The in vivo part of the study is to evaluate circulating CXCL10 levels in SSc subjects taking iloprost, either alone or in addition to other treatments (disease-modifying anti-rheumatic drugs, DMARDs and corticosteroids, CCs), and in a group of SSc subjects without therapy previously analyzed [14]. Here, CXCL10 is linked to systemic sclerosis.